BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...forodesine) fenretinide (4-hpr) Quisinostat (JNJ-26481585) Suberohydroxamic acid phenyl ester (SHAPE), remetinostat (shp-141, SHAPE) lacutamab (IPH4102) Sofusa anti-PD1 ST-001 nanoFenretinide exoIL-12 TTI-621 (SIRPaFc, SIRPalphaFc) BNZ-1 Cobomarsen (MRG-106) hypericin...
BioCentury | Aug 19, 2020

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

Chinook hooks $106M, soon to test NASDAQ’s watersChinook Therapeutics Inc. raised $106 million in a venture round as it prepares to reverse-merge with Aduro Biotech Inc. (NASDAQ:ADRO). New investors in the kidney disease company include...
BioCentury | Aug 11, 2020
Product Development

BIOEquality, data sharing and deals: a BioCentury podcast

BIO is calling on biopharmaceutical companies to put their pledges on social justice into practice as the trade group launches an initiative that aims to diversify the biotech workforce and ensure that...
BioCentury | Jul 17, 2020

Survey: biotechs adapting to COVID-19 era, optimistic about 2021

As biotechs look ahead to 2021, they may not see an end to the pandemic but they are optimistic that virtually all business activities will rebound to some extent, reflecting a net positive outlook. A...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Olivier Brandicourt will join its board. Brandicourt, who retired as CEO of Sanofi (Euronext:SAN; NASDAQ:SNY) last year, also plans to join Blackstone Group as a senior adviser....
BioCentury | Jan 4, 2020

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BioCentury | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

...after hours trading (See “FDA accepts Acer, Kala NDAs before funding lapse” ). Servier returns MRG-110...
...Thursday after disclosing in its 2Q19 earnings that Servier (Neuilly-sur-Seine, France) has discontinued development of MRG-110...
...miR-92a - MicroRNA-92a; miR-155 - MicroRNA-155; BioCentury Staff Cobomarsen (MRG-106) Inveltys, LE-MPP, Loteprednol etabonate mucosal penetrating particle (KPI-121) MRG-110 (S95010) MRG-201...
BioCentury | May 22, 2019
Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

Insmed raises $250M follow-on Insmed Inc. (NASDAQ:INSM) raised $250 million in a follow-on through the sale of 9.6 million shares at $26. The price is a 7% discount to Insmed's Monday close of $28.07, when...
BioCentury | Apr 26, 2019
Emerging Company Profile

ProNeurogen: Angiotensin peptides for vascular cognitive impairment

By developing native and glycosylated forms of the angiotensin-(1-7) peptide for vascular cognitive impairment, ProNeurogen hopes to plug a treatment gap that repurposed Alzheimer's disease drugs have failed to fill. There are no therapies approved...
BioCentury | Feb 11, 2019
Distillery Therapeutics


INDICATION: Neurology Mouse studies identified a peptide agonist of MAS receptor that could help treat vascular dementia. The compound consists of the first six residues of angiotensin(1-7) - an endogenous peptide ligand of the MAS receptor...
Items per page:
1 - 10 of 111